Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals Breast Cancer at ASCO 2019: IO, CDK4/6i, and New Approvals

Drs Miller and Burstein discuss advances presented at ASCO 2019 in immunotherapy, CDK4/6 inhibitors, and neoadjuvant TDM-1 therapies for breast cancer.Medscape Oncology

Source: Medscape Allergy Headlines - June 7, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Commentary Source Type: news